Search

Displaying results 3071 - 3080 of 4238 in total
  1. Drug

    B27PD

    go.drugbank.com/drugs/DB16289
    Investigational

    B27PD is under investigation in clinical trial NCT01195948 (Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis).

  2. Drug

    AVP-21D9

    go.drugbank.com/drugs/DB17798
    Investigational

    AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.[A259522]

  3. Drug

    Fluoroacetic acid F-18

    go.drugbank.com/drugs/DB15202
    Investigational

    Fluoroacetic acid F-18 is under investigation in clinical trial NCT01320787 (18-F-Fluoroacetate as PET Imaging Agent).

  4. Drug

    Perflubron

    go.drugbank.com/drugs/DB05791
    Investigational

    Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

  5. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase protease is a mix of enzymes, formed by...

  6. Drug

    Troleandomycin

    go.drugbank.com/drugs/DB13179
    Approved

    A macrolide antibiotic that is similar to erythromycin.

  7. Drug

    Econazole

    go.drugbank.com/drugs/DB01127
    Approved

    A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.

  8. Drug

    Dimenoxadol

    go.drugbank.com/drugs/DB01461
    ExperimentalIllicit

    In the United States it is classified as a Schedule I controlled drug. … Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative.

  9. Drug

    Dibromothymoquinone

    go.drugbank.com/drugs/DB04646
    Experimental

    At low concentrations, this compound inhibits reduction of conventional hydrophilic electron acceptors, probably acting as a plastoquinone antagonist. … At higher concentrations, it acts as an electron acceptor, intercepting electrons either before or at the site of its inhibitory activity. [PubChem]

  10. Drug

    NSI-566

    go.drugbank.com/drugs/DB17954
    Investigational

    Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]